Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma

NCT01829568 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01829568
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01829568 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 26, 2013
Completion date
June 6, 2027
Enrollment
33 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

ann arbor stage ii grade 1 contiguous follicular lymphoma, ann arbor stage ii grade 1 non-contiguous follicular lymphoma, ann arbor stage ii grade 2 contiguous follicular lymphoma, ann arbor stage ii grade 2 non-contiguous follicular lymphoma, ann arbor stage ii grade 3 contiguous follicular lymphoma, ann arbor stage ii grade 3 non-contiguous follicular lymphoma, ann arbor stage iii grade 1 follicular lymphoma, ann arbor stage iii grade 2 follicular lymphoma, ann arbor stage iii grade 3 follicular lymphoma, ann arbor stage iv grade 1 follicular lymphoma, ann arbor stage iv grade 2 follicular lymphoma, ann arbor stage iv grade 3 follicular lymphoma